543 related articles for article (PubMed ID: 25673718)
1. Contrasting effects of W781V and W780V mutations in helix N of herpes simplex virus 1 and human cytomegalovirus DNA polymerases on antiviral drug susceptibility.
Piret J; Goyette N; Eckenroth BE; Drouot E; Götte M; Boivin G
J Virol; 2015 Apr; 89(8):4636-44. PubMed ID: 25673718
[TBL] [Abstract][Full Text] [Related]
2. Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases.
Zarrouk K; Zhu X; Goyette N; Piret J; Shi R; Boivin G
Antiviral Res; 2021 Apr; 188():105046. PubMed ID: 33588012
[TBL] [Abstract][Full Text] [Related]
3. Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet.
Zarrouk K; Zhu X; Pham VD; Goyette N; Piret J; Shi R; Boivin G
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0039021. PubMed ID: 33875432
[TBL] [Abstract][Full Text] [Related]
4. Amino acid changes within conserved region III of the herpes simplex virus and human cytomegalovirus DNA polymerases confer resistance to 4-oxo-dihydroquinolines, a novel class of herpesvirus antiviral agents.
Thomsen DR; Oien NL; Hopkins TA; Knechtel ML; Brideau RJ; Wathen MW; Homa FL
J Virol; 2003 Feb; 77(3):1868-76. PubMed ID: 12525621
[TBL] [Abstract][Full Text] [Related]
5. Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet.
Tchesnokov EP; Gilbert C; Boivin G; Götte M
J Virol; 2006 Feb; 80(3):1440-50. PubMed ID: 16415021
[TBL] [Abstract][Full Text] [Related]
6. Herpesvirus DNA polymerases: Structures, functions and inhibitors.
Zarrouk K; Piret J; Boivin G
Virus Res; 2017 Apr; 234():177-192. PubMed ID: 28153606
[TBL] [Abstract][Full Text] [Related]
7. Genotypic characterization of the DNA polymerase and sensitivity to antiviral compounds of foscarnet-resistant herpes simplex virus type 1 (HSV-1) derived from a foscarnet-sensitive HSV-1 strain.
Saijo M; Suzutani T; Morikawa S; Kurane I
Antimicrob Agents Chemother; 2005 Feb; 49(2):606-11. PubMed ID: 15673740
[TBL] [Abstract][Full Text] [Related]
8. Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids.
Bestman-Smith J; Boivin G
J Virol; 2003 Jul; 77(14):7820-9. PubMed ID: 12829822
[TBL] [Abstract][Full Text] [Related]
9. 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases.
Schnute ME; Cudahy MM; Brideau RJ; Homa FL; Hopkins TA; Knechtel ML; Oien NL; Pitts TW; Poorman RA; Wathen MW; Wieber JL
J Med Chem; 2005 Sep; 48(18):5794-804. PubMed ID: 16134946
[TBL] [Abstract][Full Text] [Related]
10. A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet.
Ducancelle A; Champier G; Alain S; Petit F; Le Pors MJ; Mazeron MC
Antivir Ther; 2006; 11(4):537-40. PubMed ID: 16856628
[TBL] [Abstract][Full Text] [Related]
11. Novel Method Based on Real-Time Cell Analysis for Drug Susceptibility Testing of Herpes Simplex Virus and Human Cytomegalovirus.
Piret J; Goyette N; Boivin G
J Clin Microbiol; 2016 Aug; 54(8):2120-7. PubMed ID: 27252463
[TBL] [Abstract][Full Text] [Related]
12. Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity.
Martin M; Azzi A; Lin SX; Boivin G
Antivir Ther; 2010; 15(4):579-86. PubMed ID: 20587851
[TBL] [Abstract][Full Text] [Related]
13. Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility.
Chou S
Antiviral Res; 2021 Nov; 195():105181. PubMed ID: 34560144
[TBL] [Abstract][Full Text] [Related]
14. Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene.
Chou S
Antiviral Res; 2017 Feb; 138():57-60. PubMed ID: 27940027
[TBL] [Abstract][Full Text] [Related]
15. Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis.
Andouard D; Mazeron MC; Ligat G; Couvreux A; Pouteil-Noble C; Cahen R; Yasdanpanah Y; Deering M; Viget N; Alain S; Hantz S
Antiviral Res; 2016 May; 129():115-119. PubMed ID: 26872863
[TBL] [Abstract][Full Text] [Related]
16. Engineering of a chimeric RB69 DNA polymerase sensitive to drugs targeting the cytomegalovirus enzyme.
Tchesnokov EP; Obikhod A; Schinazi RF; Götte M
J Biol Chem; 2009 Sep; 284(39):26439-46. PubMed ID: 19622750
[TBL] [Abstract][Full Text] [Related]
17. Murine cytomegalovirus resistant to antivirals has genetic correlates with human cytomegalovirus.
Scott GM; Ng HL; Morton CJ; Parker MW; Rawlinson WD
J Gen Virol; 2005 Aug; 86(Pt 8):2141-2151. PubMed ID: 16033961
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a non-radioactive DNA polymerase assay for studying cytomegalovirus resistance to foscarnet.
Ducancelle A; Alain S; Petit F; Sanson Le Pors MJ; Mazeron MC
J Virol Methods; 2007 May; 141(2):212-5. PubMed ID: 17197042
[TBL] [Abstract][Full Text] [Related]
19. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments.
Cihlar T; Fuller MD; Cherrington JM
J Virol; 1998 Jul; 72(7):5927-36. PubMed ID: 9621055
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV(r) virus.
Saijo M; Yasuda Y; Yabe H; Kato S; Suzutani T; De Clercq E; Niikura M; Maeda A; Kurane I; Morikawa S
J Med Virol; 2002 Sep; 68(1):99-104. PubMed ID: 12210436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
